PUBLISHER: TechSci Research | PRODUCT CODE: 1886473
PUBLISHER: TechSci Research | PRODUCT CODE: 1886473
We offer 8 hour analyst time for an additional research. Please contact us for the details.
The Global Chikungunya Fever Market, valued at USD 493.23 Million in 2024, is projected to experience a CAGR of 7.28% to reach USD 751.91 Million by 2030. The Global Chikungunya Fever Market encompasses therapeutic interventions, diagnostic solutions, and preventive measures addressing this mosquito-borne viral infection, primarily transmitted by *Aedes aegypti* and *Aedes albopictus* mosquitoes.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 493.23 Million |
| Market Size 2030 | USD 751.91 Million |
| CAGR 2025-2030 | 7.28% |
| Fastest Growing Segment | Serological Tests |
| Largest Market | South America |
Key Market Drivers
The rising global incidence of Chikungunya Fever significantly drives market demand for diagnostic tools, therapeutic interventions, and preventive vaccines. Heightened disease prevalence necessitates more widespread testing and treatment, accelerating product development. According to the European Centre for Disease Prevention and Control, as of November 2024, approximately 480,000 Chikungunya cases were reported worldwide, underscoring the expanding public health challenge.
Key Market Challenges
The persistent gap in surveillance capabilities and diagnostic readiness represents a significant impediment to the growth of the Global Chikungunya Fever Market. This challenge directly hampers the market by delaying timely detection and effective management of the disease, thereby limiting the demand for diagnostic solutions and subsequent therapeutic interventions. When infections go undetected or are misdiagnosed, the market for related products cannot expand to its full potential.
Key Market Trends
Advances in mRNA Vaccine Technology represent a pivotal trend, expediting the development cycle for Chikungunya vaccines by enabling rapid antigen identification and flexible manufacturing processes. This technology allows for quicker responses to emerging viral strains and offers the potential for high-efficacy profiles. According to *Vaccine*, in June 2023, Moderna's mRNA-1388 Chikungunya vaccine candidate demonstrated favorable safety and immunogenicity in a Phase 1 study, eliciting substantial and persistent neutralizing antibody responses in healthy adults.
In this report, the Global Chikungunya Fever Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies presents in the Global Chikungunya Fever Market.
Global Chikungunya Fever Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: